(Q28379500)

1

0 references

B Ji

2

0 references

C Truffot-Pernot

3

0 references

J Grosset

Antimicrobial Agents and Chemotherapy

4

0 references

language of work or name

English

0 references

publication date

March 1997

0 references

published in

0 references

volume

41

0 references

issue

3

0 references

page(s)

607-10

0 references

cites work

Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163759

Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163759

The emergence of drug-resistant tuberculosis in New York City

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163759

In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163759

Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163759

In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163759

Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163759

Pharmacokinetics of isepamicin

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163759

Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163759

Present status of chemotherapy for tuberculosis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163759

Tuberculosis: a global overview of the situation today

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163759

An overview of the safety of isepamicin in adults.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163759

[Chemotherapeutic studies on advanced tuberculosis in mice]

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163759

Statistics in practice. Comparing the means of several groups.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163759

Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163759

Drug-resistant tuberculosis in a southern California hospital. Trends from 1969 to 1984.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163759

Improved outcomes for patients with multidrug-resistant tuberculosis.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=163759

Overview of the efficacy of isepamicin in the adult core clinical trial programme

27 November 2018

1 reference

12 December 2020

Resistance to antituberculosis drugs in Japan

1 reference

12 December 2020

Experimental "in vivo" studies of new antituberculosis drugs: capreomycin, ethambutol, rifampicin

1 reference

12 December 2020

[Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)]

1 reference

12 December 2020

Amikacin in the treatment of pulmonary tuberculosis

1 reference

12 December 2020